Skip to main content
Log in

Risperdal reigns supreme in schizophrenia

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Decision Resources.Although Generic Erosion Looms for Risperdal, the Drug Remains First-Line Antipsychotic in the Treatment of Schizophrenia. Media Release: 10 Jul 2008. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Risperdal reigns supreme in schizophrenia. Pharmacoecon. Outcomes News 558, 4 (2008). https://doi.org/10.2165/00151234-200805580-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805580-00011

Keywords

Navigation